Functional Genomics Reveals Diverse Cellular Processes That Modulate Tumor Cell Response to Oxaliplatin

Abstract

Oxaliplatin is widely used to treat colorectal cancer, as both adjuvant therapy for resected disease and palliative treatment of metastatic disease. However, a significant number of patients experience serious side effects, including prolonged neurotoxicity, from oxaliplatin treatment creating an urgent need for biomarkers of oxaliplatin response or resistance to direct therapy to those most likely to benefit. As a first step to improve selection of patients for oxaliplatin-based chemotherapy, we have conducted an in vitro cell-based small interfering RNA (siRNA) screen of 500 genes aimed at identifying genes whose loss of expression alters tumor cell response to oxaliplatin. The siRNA screen identified twenty-seven genes, which when silenced, significantly altered colon tumor cell line sensitivity to oxaliplatin. Silencing of a group of putative resistance genes increased the extent of oxaliplatin-mediated DNA damage and inhibited cell-cycle progression in oxaliplatin-treated cells. The activity of several signaling nodes, including AKT1 and MEK1, was also altered. We used cDNA transfection to overexpress two genes (LTBR and TMEM30A) that were identified in the siRNA screen as mediators of oxaliplatin sensitivity. In both instances, overexpression conferred resistance to oxaliplatin. In summary, this study identified numerous putative predictive biomarkers of response to oxaliplatin that should be studied further in patient specimens for potential clinical application. Diverse gene networks seem to influence tumor survival in response to DNA damage by oxaliplatin. Finally, those genes whose loss of expression (or function) is related to oxaliplatin sensitivity may be promising therapeutic targets to increase patient response to oxaliplatin. Mol Cancer Res; 9(2); 173-82. Ó2010 AACR.

Prognostic Factors for Recurrence after Tegafur-uracil Plus Leucovorin Adjuvant Chemotherapy in Patients with Colorectal Cancer

“…Third, our study did not include the biomarkers associated with CRC recurrence or molecular markers associated with response to anticancer agents. Several molecular markers have been shown to be satisfactory predictors of the efficacy of 5-FU-based or L-OHP-based chemotherapy [21][22][23][24][25][26][27] .…”

Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment

“…However, these findings appear to be controversial, since at least two studies4,14 found no association between DNA repair proteins and oxaliplatin resistance. In our experiments, we found ERCC1 to be downregulated in 48 hours at 5 μM of oxaliplatin exposure.…”

Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling

“…For the γH2AX assay, the double-stranded breaks were detected using the EpiQuik In Situ DNA Damage Assay kit (Epigentek, Farmingdale, NY, USA) according to the manufacturer’s instructions. The absorbance signal was normalized to the cell number in each sample, and the samples were calculated relative to the untreated control4445.…”